Michael Yee Downgrades Moderna to “Hold” Michael Yee, in his recent interview with Yahoo Finance, explained his decision… This article Michael Yee’s Moderna Downgrade appeared first on Guerilla Stock Trading. Source link
Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key products and predicted 2025 sales below its forecast for the current year, sending its shares closer to a four-year low. Shares of the vaccine maker tumbled 17.1% to $65.88 at midday. The company expects sales…
The Approval Without an Emergency In a move that has sparked considerable debate, the FDA approved a new… This article FDA approves new COVID-19 vaccine for babies… but there’s no emergency? What’s really going on? 🤔 appeared first on Guerilla Stock Trading. Source link
$90.15 +3.31 (+3.81%) (As of 03:08 PM ET) 52-Week Range $62.55 ▼ $170.47 Price Target $124.07 Biotechnology company Moderna Inc. NASDAQ: MRNA stock rocked investors with a 30% drop following its second-quarter 2024 earnings release. The company disappointed investors when it revised its respiratory franchise revenue forecast lower by half a billion dollars. However, shares were…
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, will adversely affect certain features and functions. The technical storage or access is strictly…